Target intelligence / Profile preview

COP9 signalosome subunit 2 (COPS2)

Target
COPS2
Molecular classification
Signalosome subunit, Multiprotein complex component, Transcription corepressor, Ubiquitin-conjugation regulator, Other (PCI domain-containing protein, as part of signalosome family)
01

Overview

COP9 signalosome subunit 2 (COPS2) is a core protein of the COP9 signalosome, an evolutionarily conserved eight-subunit complex that regulates protein turnover by mediating deneddylation of cullin-RING ubiquitin ligases (CRLs). As a transcriptional corepressor, COPS2 binds nuclear hormone receptors and other transcriptional regulators, facilitating gene expression control. In embryonic stem cells, COPS2 maintains pluripotency and cell cycle progression by preventing the proteasomal degradation of Nanog and other critical factors. It also interacts with oncogenic transcription factors (e.g., Snail), influencing tumorigenic signaling pathways. Upregulation and deregulation of COPS2 are implicated in cancer progression, including colorectal and hepatocellular carcinomas, and the protein also plays roles in DNA repair, neuronal differentiation, and early development. Systemic disruption of COPS2 has pronounced effects, including cell cycle arrest and embryonic lethality, making it a promising but challenging therapeutic target[1][2][3][4][5][7].

Other names
COP9 signalosome complex subunit 2CSN2TRIP15SGN2Signalosome subunit 2TR-interacting protein 15Alien homologThyroid receptor-interacting protein 15TRIP-15ALIENJAB1-containing signalosome subunit 2
02

Mechanism of action

Drugs targeting the COP9 signalosome would inhibit its protein-deneddylation activity, leading to increased ubiquitin ligase activity and altered protein degradation (especially of oncogenes and tumor suppressors). Indirect regulation of protein turnover (degradation of transcription factors such as Snail, Nanog).

03

Biological functions

Protein deneddylation and regulation of cullin-RING ubiquitin ligases (CRL)Transcription corepressor activity (interacts with nuclear hormone and other transcriptional regulators)Regulation of protein phosphorylation (p53, c-Jun, IkappaBalpha/NFKBIA)Cell cycle regulation, maintenance of pluripotency in embryonic stem cells, somatic cell reprogrammingDNA repair and fidelity, neuronal differentiation
04

Disease associations

Cancer (colorectal, hepatocellular carcinoma, lung)Xeroderma pigmentosum, complementation group EInvolved in other proliferative diseases (tumorigenesis, carcinogenesis)Other (early development, neuronal differentiation)
05

Safety considerations

Essential for normal cellular function; systemic inhibition could cause significant cellular toxicity, cell cycle arrest, and embryonic arrestLoss of COPS2 disrupts pluripotency, cell proliferation, and differentiation; this may present challenges for therapeutic targeting
06

Interacting drugs

Direct drug interactions are not specified for COPS2 alone in the results, but the COP9 signalosome complex has been explored as a broad drug target for cancer and parasitic infections; no approved inhibitors targeting COPS2 specifically are currently listed
07

Biomarkers

High expression in tumor tissues (e.g., hepatocellular carcinoma), correlation with poor prognosisCOPS2 mRNA downregulation by miR-15a–3p as a marker for PR progression in colorectal cancer

Beyond the preview

Go deeper on COP9 signalosome subunit 2 (COPS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COP9 signalosome subunit 2 (COPS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call